Interim results from a phase II study of tislelizumab combined with radiotherapy as bladder-preserving treatment for patients with high-risk non-muscle-invasive bladder cancer (HR NMIBC) unresponsive to bacillus Calmette-Guerin (BCG).

被引：0
|
作者：
Li, Zhiyong
He, Liru
Yao, Kai
Ye, Yunlin
Li, Xiangdong
Qin, Zike
Han, Hui
Zhou, Fangjian
Liu, Zhuowei
机构：
[1] Sun Yat Sen Univ, Dept Urol, Canc Ctr, Guangzhou, Peoples R China
[2] Sun Yat Sen Univ, Dept Radiat Oncol, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med,Canc Ctr, Guangzhou, Peoples R China
[3] Sun Yat Sen Univ, Guangdong Prov Clin Res Ctr Canc, State Key Lab Oncol Southern China, Collaborat Innovat Ctr Canc Med,Canc Ctr,Dept Uro, Guangzhou, Peoples R China
[4] Sun Yat Sen Univ, Dept Urol, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med,Canc Ctr, Guangzhou, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16600
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Preliminary results from a phase II study of tislelizumab combined with radiotherapy as bladder-preserving treatment for patients with high-risk non-muscle-invasive bladder cancer (HR NMIBC) unresponsive to bacillus Calmette-Guerin (BCG).
    Li, Zhiyong
    He, Liru
    Li, Xiangdong
    Yao, Kai
    Liu, Yang
    Qin, Zike
    Ye, Yunlin
    Zhou, Fangjian
    Liu, Zhuowei
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [2] Punch: Preliminary results from a phase II study of intra-arterial chemotherapy (IAC) combined with tislelizumab and bacillus Calmette-Guerin (BCG) in high-risk non-muscle-invasive bladder cancer (HR NMIBC).
    Wang, Zongren
    Zhan, Wenhao
    Huang, Bin
    Luo, Cheng
    Chen, Lingwu
    Chen, Junxing
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 618 - 618
  • [3] Updated Interim Analysis from Keynote-057: Pembrolizumab Monotherapy for Patients with High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG)
    Krieger, Laurence
    de Wit, Ronald
    Kulkarni, Girish S.
    Uchio, Edward M.
    Boormans, Joost L.
    Roumiguie, Mathieu
    Singer, Eric A.
    Bajorin, Dean F.
    Kamat, Ashish M.
    Grivas, Petros
    Seo, Ho Kyung
    Nishiyama, Hiroyuki
    Konety, Badrinath R.
    Nam, Kijoeng
    Kapadia, Ekta
    Frenkl, Tara L.
    Balar, Arjun Vasant
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2019, 15 : 52 - 53
  • [4] Pembrolizumab for high-risk (HR) non-muscle invasive bladder cancer (NMIBC) unresponsive to bacillus Calmette-Guerin (BCG): Phase II KEYNOTE-057 trial
    de Wit, R.
    Kulkarni, G. S.
    Uchio, E.
    Singer, E. A.
    Krieger, L.
    Grivas, P.
    Bajorin, D.
    Seo, H. K.
    Mourey, L.
    Kamat, A.
    Nishiyama, H.
    Kapadia, E.
    Nam, K.
    Frenkl, T.
    Balar, A.
    ANNALS OF ONCOLOGY, 2018, 29 : 304 - 304
  • [5] The Effectiveness of Bacillus Calmette-Guerin (BCG) Maintenance Treatment in Intermediate and High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)
    Kim, B.
    Ha, J.
    Park, C.
    Kim, C.
    UROLOGY, 2012, 80 (03) : S215 - S216
  • [6] Bacillus Calmette-Guerin (BCG) unresponsive non-muscle-invasive bladder cancer: are the subgroups equal?
    Tan, Wei Shen
    Grajales, Valentina
    Bree, Kelly
    Li, Roger
    Nogueras-Gonzalez, Graciela M.
    Navai, Neema
    Dinney, Colin
    Kamat, Ashish M.
    BJU INTERNATIONAL, 2023, 132 (04) : 384 - 386
  • [7] Pembrolizumab in patients with Bacillus Calmette Guerin (BCG)-unresponsive, high-risk non-muscle-invasive bladder cancer (NMIBC): Phase 2 KEYNOTE-057 study
    de Wit, R.
    Kamat, A. M.
    Bellmunt, J.
    Choueiri, T. K.
    Nam, K.
    De Santis, M.
    Dreicer, R.
    Hahn, N. M.
    Perini, R.
    Siefker-Radtke, A. O.
    Sonpavde, G.
    Witjes, J. A.
    Keefe, S.
    Bajorin, D.
    ANNALS OF ONCOLOGY, 2016, 27
  • [8] Pembrolizumab with favezelimab or vibostolimab for patients with High-Risk (HR) bacillus Calmette-Guerin (BCG)-unresponsive Non-Muscle-Invasive Bladder Cancer (NMIBC): Phase 2 KEYNOTE-057 cohort C
    Necchi, A.
    Shore, N. D.
    Gupta, S.
    Kulkarni, G.
    Dave, H.
    Kapadia, E.
    Zhao, Q.
    Kamat, A.
    EUROPEAN UROLOGY, 2023, 83 : S748 - S748
  • [9] SAFETY AND TOLERABILITY OF TAR-200 MONOTHERAPY IN PATIENTS WITH BACILLUS CALMETTE-GUERIN (BCG)UNRESPONSIVE HIGH-RISK NON-MUSCLE-INVASIVE BLADDER CANCER (HR NMIBC) IN SUNRISE-1
    Siamak, Daneshmand
    Daniel, Zainfeld
    Christopher, Pieczonka
    Giuseppe, Simone
    Michiel, S. van der Heijden
    Martin, Bogemann
    David, S. Morris
    Philipp, Spiegelhalder
    Laurence, H. Belkoff
    Karel, Decaestecker
    Harm, Arentsen
    Shalaka, Hampras
    Christopher, J. Cutie
    Hussein, Sweiti
    Katharine, Stromberg
    Jason, Martin
    Abhijit, Shukla
    Joseph, M. Jacob
    Evanguelos, Xylinas
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2025, 43 (03)
  • [10] KEYNOTE-057: Phase 2 study of pembrolizumab for patients (pts) with Bacillus Calmette Guerin (BCG)unresponsive, high-risk non-muscle-invasive bladder cancer (NMIBC)
    Kamat, Ashish M.
    Bellmunt, Joaquim
    Choueiri, Toni K.
    Nam, Kijoeng
    De Santis, Maria
    Dreicer, Robert
    Hahn, Noah M.
    Perini, Rodolfo F.
    Siefker-Radtke, Arlene O.
    Sonpavde, Guru
    De Wit, Ronald
    Witjes, Alfred
    Keefe, Stephen Michael
    Bajorin, Dean F.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
12345